|
05 Nov 2019 |
SciRhom Initiates First-In-Class Antibody Development Program to Treat Major Autoimmune Diseases
|
|
04 Nov 2019 |
Compugen Announces FDA Clearance of IND Application for COM902
|
|
04 Nov 2019 |
Harbour BioMed Announces Initiation of First-in-human Study of Next-generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors
|
|
01 Nov 2019 |
Pinteon Therapeutics Launches Phase 1 Trial of Novel Tau Antibody that Targets a Potent Driver of Neurodegenerative Disease
|
|
01 Nov 2019 |
Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis
|
|
31 Oct 2019 |
Daiichi Sankyo Initiates Clinical Trial with its 4th DXd Antibody Drug Conjugate, DS-7300, in Collaboration with Sarah Cannon Research Institute
|
|
30 Oct 2019 |
CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma
|
|
30 Oct 2019 |
FDA Accepts Genentech’s Biologics License Application for Satralizumab for Neuromyelitis Optica Spectrum Disorder
|
|
29 Oct 2019 |
Harpoon Therapeutics Presents Preclinical Data for HPN328, a DLL3-targeting T Cell Engager, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
|
|
29 Oct 2019 |
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer
|
|
29 Oct 2019 |
Intravenous Benlysta is the first biologic treatment to be approved for children with lupus in Europe
|
|
29 Oct 2019 |
Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
|
|
29 Oct 2019 |
European Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
|
|
29 Oct 2019 |
MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
|
|
28 Oct 2019 |
Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer
|
|
28 Oct 2019 |
Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
|
|
28 Oct 2019 |
NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
|
|
28 Oct 2019 |
Y-mAbs Announces Positive Omburtamab Clinical Data
|
|
28 Oct 2019 |
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
|
|
28 Oct 2019 |
Zymeworks Announces Phase 1 Data for ZW25 in Combination with Chemotherapy in Advanced Gastroesophageal Adenocarcinoma at AACR-NCI-EORTC International Conference
|
|
28 Oct 2019 |
Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA
|
|
28 Oct 2019 |
Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar candidate FYB202
|
|
27 Oct 2019 |
Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences
|
|
25 Oct 2019 |
MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
|
|
25 Oct 2019 |
Y-mAbs Announces Naxitamab Update
|
